- Conditions
- Proliferative Diabetic Retinopathy (PDR)
- Interventions
- Vitrectomy, Endolaser, Faricimab, Panretinal Photocoagulation (PRP)
- Procedure · Device · Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 34
- States / cities
- Huntington Beach, California • Loma Linda, California • San Francisco, California + 30 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–64
of 64
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Retinopathy
- Interventions
- Runcaciguat (BAY1101042), Placebo
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- Modesto, California • Lakeland, Florida • Pinellas Park, Florida + 6 more
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Charles C Wykoff, PhD, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Houston, Texas • Katy, Texas • Kingwood, Texas + 1 more
- Conditions
- Non-Proliferative Diabetic Retinopathy
- Interventions
- Faricimab
- Drug
- Lead sponsor
- Greater Houston Retina Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 16
- States / cities
- Bakersfield, California • Modesto, California • Orlando, Florida + 13 more
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Aflibercept, Endolaserless Vitrectomy
- Drug · Procedure
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Nonproliferative Diabetic Retinopathy
- Interventions
- AKB-9778, Placebo
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 53
- States / cities
- Phoenix, Arizona • Arcadia, California • Bakersfield, California + 47 more
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Brolucizumab 6 mg, Panretinal photocoagulation laser
- Biological · Procedure
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Beverly Hills, California • Fullerton, California + 32 more
- Conditions
- Retinal Detachment, Diabetic Retinopathy
- Interventions
- Avastin (bevacizumab), Sham injection
- Drug · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Retinal Detachment, Vitrectomy, Proliferative Vitreoretinopathy, Diabetic Retinopathy
- Interventions
- 1000 centistoke silicone oil, 5000 centistoke silicone oil
- Procedure
- Lead sponsor
- Mid Atlantic Retina
- Other
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Moderate Non-proliferative Diabetic Retinopathy
- Interventions
- Alpha Lipoic Acid
- Dietary Supplement
- Lead sponsor
- Ferris State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Big Rapids, Michigan • Grand Rapids, Michigan
- Conditions
- Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
- Interventions
- Faricimab Injection, sham treatment
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Diabetic Retinopathy
- Interventions
- BI 1467335, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 16
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Beverly Hills, California + 13 more
- Conditions
- Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
- Interventions
- VX-01, Placebo
- Drug
- Lead sponsor
- Vantage Biosciences Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Palo Alto, California • Santa Barbara, California + 5 more
- Conditions
- Diabetic Retinopathy
- Interventions
- BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- ranibizumab, Laser photocoagulation
- Drug · Procedure
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Retinopathy, Diabetic
- Interventions
- Aflibercept Injection, Sham injection
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York